Los puntos clave no están disponibles para este artículo en este momento.
Grade 3-4 cytokine release syndrome occurred in 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic leukemia. Clinicians should be aware of expanding use of this breakthrough therapy and implications for critical care units in cancer centers.
Fitzgerald et al. (Thu,) studied this question.